Coley Seeks HCV Partner For Actilon
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm suspends independent development of the hepatitis C agent in hopes of finding a partner with resources and expertise to share the risk.
You may also be interested in...
Array/VentiRx Partner On Toll-Like Receptor Drugs In Oncology, Allergy
Through a licensing agreement, VentiRx gains rights to Array’s TLR program containing several development candidates
Array/VentiRx Partner On Toll-Like Receptor Drugs In Oncology, Allergy
Through a licensing agreement, VentiRx gains rights to Array’s TLR program containing several development candidates
Anadys/Novartis Hepatitis C Candidate Could Be Back In The Clinic By Year End
A 13-week preclinical toxicology study of ANA975 aims to explain dose dependence and immune stimulation concerns that led to FDA’s clinical hold for the toll-like receptor agonist.